UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE
ACT OF 1934
December 31, 1995
For the quarterly period ended _________________________________________________
[_] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from _______________________ to ______________________
1-10285
Commission File Number: ________________________________________________________
BIOMAGNETIC TECHNOLOGIES, INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
California 95-2647755
- --------------------------------------------- --------------------------------
(State or other jurisdiction of incorporation (I.R.S.Employer
or organization) Identification No.)
9727 Pacific Heights Boulevard, San Diego, California 92121-3719
- --------------------------------------------------------------------------------
(Address of principal executive offices) (zip code)
(619) 453-6300
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
- --------------------------------------------------------------------------------
(Former name, former address and formal fiscal year,
if changed since last report)
Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. [X] Yes [_] No
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS
Indicate by check mark whether the registrant has filed all documents and
reports required to be filed by Sections 12, 13 or 15(d) of the Securities
Exchange Act of 1934 subsequent to the distribution of securities under a plan
confirmed by a court. [_] Yes [_] No
APPLICABLE ONLY TO CORPORATE ISSUERS:
Indicate the number of shares outstanding of each of the issuer's classes of
common stock as of the latest practicable date.
As of February 1, 1996 Registrant had only one class of common stock of
which there were 39,932,174 shares outstanding.
PART I -- FINANCIAL INFORMATION
Item 1. Financial Statements
BIOMAGNETIC TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)
December 31,
1995 September 30,
(Unaudited) 1995
------------ -------------
ASSETS
Cash and cash equivalents $ 1,467 $ 2,314
Short-term investments 10,530 10,516
Accounts receivable 722 774
Inventories 2,961 2,477
Prepaid expenses and other current assets 501 456
----------- ------------
Total current assets 16,181 16,537
Property and equipment 9,772 9,819
Less accumulated depreciation and amortization (7,871) (7,894)
----------- ------------
1,901 1,925
Restricted cash 1,100 1,100
Other assets 612 562
----------- ------------
Total assets $ 19,794 $ 20,124
=========== ============
LIABILITIES AND SHAREHOLDERS' EQUITY
Accounts payable $868 $787
Accrued salaries and employee benefits 607 611
Accrued liabilities 1,637 1,009
Customer deposits 5,870 3,856
----------- ------------
Total current liabilities 8,982 6,263
Other liabilities 510 493
----------- ------------
Total liabilities 9,492 6,756
Shareholders' Equity
Common stock -- no par value, 60,000,000 shares
authorized; 39,932,174 and 39,921,174 shares issued and
outstanding in December and September, respectively 78,422 78,415
Accumulated deficit (68,120) (65,047)
----------- ------------
Total shareholders' equity 10,302 13,368
----------- ------------
Total liabilities and shareholders' equity $ 19,794 $ 20,124
=========== ============
BIOMAGNETIC TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)
(In thousands, except per-share amounts)
Three Months Ended
December 31,
1995 1994
----------- -----------
Product sales $ 35 $ 2,719
Contract research 46
Interest income 160 31
----------- -----------
Total revenues 195 2,796
Cost of product sales 427 1,477
Contract research costs 2 48
Research and development 1,522 1,251
Marketing, general and administrative 1,308 1,093
Interest expense 9 236
----------- -----------
Total expenses 3,268 4,105
----------- -----------
Net loss $(3,073) $(1,309)
=========== ===========
Net Loss per Share $ (0.08) $ (0.13)
=========== ===========
Weighted average number of
shares outstanding 39,932 10,028
=========== ===========
BIOMAGNETIC TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(In thousands)
THREE MONTHS ENDED
DECEMBER 31,
1995 1994
----------- -----------
OPERATING ACTIVITIES
Net loss $(3,073) $(1,309)
Adjustments to reconcile net loss to net
cash used for operating activities:
Depreciation and amortization 226 346
Interest expense 99
Changes in operating assets & liabilities:
Accounts receivable 52 47
Prepaid and other current assets (45) 144
Inventories (484) 265
Accounts payable 81 (115)
Accrued liabilities 628 643
Accrued salaries and employee benefits (4) (86)
Customer deposits 2,014 1,094
Changes in other operating assets and liabilities (33) (29)
Net cash (used for) provided by operating activities (638) 1,099
INVESTING ACTIVITIES
Change in short-term investments (14)
Capital expenditures (202) (29)
----------- -----------
Net cash used for investing activities (216) (29)
FINANCING ACTIVITIES
Proceeds from issuance of short-term debt 500
Net proceeds from sale of common stock 7
----------- -----------
Net cash provided by financing activities 7 500
----------- -----------
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS (847) 1,570
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 2,314 754
----------- -----------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 1,467 $ 2,324
=========== ===========
BIOMAGNETIC TECHNOLOGIES, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. Basis of Presentation
---------------------
The unaudited condensed consolidated financial statements included herein
include the accounts of Biomagnetic Technologies, Inc. and its subsidiary (the
"Company") and have been prepared in accordance with the rules and regulations
of the Securities and Exchange Commission. Certain information and footnote
disclosures normally included in financial statements prepared in accordance
with generally accepted accounting principles have been condensed or omitted
pursuant to such rules and regulations. Although the Company believes that the
disclosures made in this report are adequate to make the information not
misleading, it is suggested that these financial statements be read in
connection with the financial statements and notes thereto included in the
Company's annual report on Form 10-K for the fiscal year ended September 30,
1995.
In the opinion of the Company, the accompanying unaudited financial statements
contain all adjustments, consisting only of normal recurring accruals,
necessary to present fairly its financial position at December 31, 1995 and the
results of operations and its cash flows for the periods presented.
The preparation of financial statements, in conformity with generally accepted
accounting principles, requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and disclosure of
contingent assets and liabilities at the date of the financial statements and
the reported amounts of revenues and expenses during the reporting period.
Actual results could differ from these estimates.
2. Net Loss per Share
------------------
Shares used in computing net loss per share include the weighted average of
common stock outstanding. Common stock equivalents are antidilutive and are
excluded from the computation of net loss per share.
3. Inventories
-----------
The composition of inventories is as follows:
December 31, September 30,
1995 1995
---- ----
Raw materials $ 486 $ 236
Work-in process 1,433 1,620
Finished goods 1,042 621
------ ------
$2,961 $2,477
====== ======
4. Magnes(R) Whole Head System Production and Delivery Risk
--------------------------------------------------------
The Company's backlog at December 31, 1995 is composed primarily of orders for
the new Magnes 2500 whole head magnetic source imaging system ("Magnes 2500
wh"), which is scheduled for delivery in fiscal 1996. As of December 31, 1995,
the development of the Magnes 2500 wh was not complete, and therefore no system
shipments took place in the first quarter. System shipments are expected to
commence in the third quarter of the current fiscal year. The delay in shipments
is a result of additional engineering effort and time required to complete the
development for the production and shipment of systems.
Although significant effort is being expended to complete the development so
that shipments can commence in fiscal 1996, there can be no assurance that this
will be accomplished. In the event such development is not completed as
anticipated, shipments could be further delayed. Such a delay could have a
material adverse effect on the Company's cash flow and cash resources. The
Company incurred a net loss of $3,073,000 for the quarter ended December 31,
1995 and has an accumulated deficit of $68,120,000 as of December 31, 1995, and
anticipates that capital and working capital expenditures in fiscal 1996 will
substantially exceed cash generated from operations. However, the Company
anticipates that existing capital resources together with its potential ability
to borrow on a short-term basis will be sufficient to complete development of
the Magnes 2500 wh and to provide operating capital required to meet its
obligations in the normal course of business through fiscal year 1996.
5
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS.
Biomagnetic Technologies, Inc. ("BTi") is a leader in magnetic source imaging
("MSI") and has developed the Magnes system, an instrument designed to assist in
the noninvasive diagnosis of a broad range of medical disorders. The Magnes
system developed by the Company uses advanced superconductor technology to
measure and locate the source of magnetic fields created by the human body.
While traditional medical imaging methods provide anatomical detail, the
measurement of the body's magnetic fields by MSI provides information about
normal and abnormal functions of the brain, heart and other organs. The Company
is focusing the development of its technology on potentially large commercial
market applications such as brain surgery, the diagnosis and surgical planning
for treatment of epilepsy and life-threatening cardiac arrhythmias.
Results of Operations
- ---------------------
Revenues for the first quarter of fiscal 1996 were $195,0000 compared to
$2,796,000 for the first quarter of fiscal 1995, and the net loss was $3,073,000
compared to a net loss of $1,309,000 for the first quarter of fiscal 1995. The
decrease in revenues and increase in net loss for the current quarter resulted
primarily from reduced Magnes system sales and higher operating expenses during
the period. The Company sold one Magnes system in the first quarter of fiscal
1995. No Magnes systems were sold in the first quarter of fiscal 1996.
The gross margin on product sales was negative for the first quarter of fiscal
1996 versus 46% for the comparable quarter last fiscal year. The negative gross
margin during the current quarter resulted from the lack of product sales,
manufacturing variances associated with new product development and normal
period costs.
Research and development expenses for the first quarter of fiscal 1996 amounted
to $1,522,000, as compared to $1,251,000 in the first quarter of the prior
fiscal year. The 22% increase was primarily due to increased spending
associated with internal product development and applications development for
the new Magnes WH system.
Marketing and general and administrative expenses amounted to $1,308,000 in the
first quarter of fiscal 1996 as compared to $1,093,000 in the first quarter of
fiscal 1995. The 20% increase is primarily due to increased marketing, sales
and trade show expenses.
Order backlog for the Company's products at December 31, 1995 was $12,100,000,
substantially all of which is for the Company's new Magnes 2500 wh system. The
Company expects to fill approximately $8,000,000 of this backlog by September
30, 1996. By comparison, order backlog was $9,341,000 at December 31, 1994. As
sales of the Company's systems typically involve transactions of $1.0 million or
more, the backlog is expected to fluctuate significantly from period to period
depending upon orders received and product installations completed during the
reporting period.
Liquidity, Capital Resources and Other Risk Factors
- ---------------------------------------------------
At December 31, 1995 the Company had net working capital of $7,199,000, a
decrease of $3,075,000 from September 30, 1995. The decline primarily reflects
the use of working capital to fund operations and purchase capital equipment.
Working capital at December 31, 1995 includes customer deposits totaling
$5,870,000, of which $3,316,000 is secured by standby letters of credit through
a credit facility with a bank.
Based on the Company's current operating plans, capital and working capital
expenditures necessary to support the completion of engineering development, and
production of the Company's products through September 30, 1996 are expected to
substantially exceed cash generated from operations and will result in a further
decline in the Company's liquidity. As of December 31, 1995 the development of
the Magnes 2500 wh was not complete and shipments anticipated to commence in the
first quarter of fiscal 1996 have been delayed. The delay is the result of
additional engineering effort and time required to complete the development for
the production and shipment of systems.
The Company believes that the Magnes 2500 wh will be completed in fiscal 1996.
Although significant effort is being expended to complete the engineering
development so that shipments can commence in fiscal 1996, there can be no
assurance that this will be accomplished. In the event such development is not
completed as anticipated,
6
shipments could be further delayed with possible negative effects on the cash
flow and cash resources of the Company. The Company anticipates that existing
capital resources together with its potential ability to borrow on a short-term
basis will be sufficient to complete development of the Magnes 2500 wh and to
provide operating capital required to meet its obligations in the normal course
of business through fiscal year 1996.
The Company's ability to meet its expected cash needs beyond fiscal 1996 will
depend on a number of factors, including the market's acceptance and sales of
the Magnes system, which cannot be accurately predicted at this time. The
Company may also attempt to obtain additional sources of funding through
government grants and strategic alliances with other entities. However, there
can be no assurance that additional funds will be available when needed and on
terms favorable to the Company, that grant applications will be approved or
funded, that applications of the Company's technology will be successfully
developed or that any agreements will be reached related to strategic alliances.
Should additional funding not be available, the Company would be required to
significantly reduce the scope of its operations.
To date the Company has been engaged principally in research and development
activities, and has made only low volume sales to research and medical
institutions primarily in Europe, and not made any MSI system sales for
commercial use in the U.S. Such sales require prior U.S. Food and Drug
Administration approval. The Company has secured FDA approval for its Magnes I
system, has applied for but not yet received approval to market its Magnes II
system in the U.S. and is planning to apply for FDA approval for its Magnes 2500
wh System. There can be no assurance that the Company will receive such
approval in the near future, which would permit the marketing of the Magnes II
and the new Magnes 2500 wh system in the United States for clinical use.
The Company is dependent on its Magnes systems as its principal product for
which there are currently few demonstrated clinical applications. Additional
clinical applications development needs to be conducted with the Magnetic Source
Imaging system at major medical centers before the Company can begin to
penetrate the commercial clinical market. There can be no assurance that a
market will develop for diagnostic or monitoring uses of the MSI system.
The Company's commercial success is highly dependent on the availability of
reimbursment for procedures using its MSI system. Reimbursement is not
currently provided for such procedures by the United States government, nor is
there any assurance that the U.S. government will authorize or budget for such
procedures in the future. To date reimbursements from third-party payors are on
a case-by-case basis. The Company also cannot predict what legislation relating
to its business or the health care industry may be enacted in the future,
including legislation relating to third party reimbursement, or what effect such
legislation may have on the results of its operations.
The Company operates in an industry characterized by rapid technological change.
New products using other technologies or improvement of existing products may
reduce the size of the potential markets for the Company's products, and may
render them obsolete or non-competitive by competitors' development of new or
different products using technology or imaging modalities that may provide or be
perceived as providing greater value than the Company's products.
7
PART II -- OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS.
None.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K.
(a) Exhibits: None
(b) Reports on Form 8-K: None
8
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
BIOMAGNETIC TECHNOLOGIES, INC.
February 7, 1996 /S/ James V. Schumacher
Date ______________________________ ____________________________________
James V. Schumacher
President and C.E.O. (Principal
Executive Officer)
February 7, 1996 /S/ Herman Bergman
Date ______________________________ ____________________________________
Herman Bergman
Acting Chief Financial Officer
(Principal Financial Officer)
9